RGD Reference Report - Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice.

Authors: Doddapattar, Prakash  Radović, Branislav  Patankar, Jay V  Obrowsky, Sascha  Jandl, Katharina  Nusshold, Christoph  Kolb, Dagmar  Vujić, Nemanja  Doshi, Lalit  Chandak, Prakash G  Goeritzer, Madeleine  Ahammer, Helmut  Hoefler, Gerald  Sattler, Wolfgang  Kratky, Dagmar 
Citation: Doddapattar P, etal., Mol Nutr Food Res. 2013 Oct;57(10):1718-28. doi: 10.1002/mnfr.201200794. Epub 2013 May 3.
RGD ID: 401842363
Pubmed: PMID:23650230   (View Abstract at PubMed)
PMCID: PMC3771820   (View Article at PubMed Central)
DOI: DOI:10.1002/mnfr.201200794   (Journal Full-text)


SCOPE: Xanthohumol (XN), a prenylated antioxidative and anti-inflammatory chalcone from hops, exhibits positive effects on lipid and glucose metabolism. Based on its favorable biological properties, we investigated whether XN attenuates atherosclerosis in western-type diet-fed apolipoprotein-E-deficient (ApoE⁻/⁻) mice.
METHODS AND RESULTS: XN supplementation markedly reduced plasma cholesterol concentrations, decreased atherosclerotic lesion area, and attenuated plasma concentrations of the proinflammatory cytokine monocyte chemoattractant protein 1. Decreased hepatic triglyceride and cholesterol content, activation of AMP-activated protein kinase, phosphorylation and inactivation of acetyl-CoA carboxylase, and reduced expression levels of mature sterol regulatory element-binding protein (SREBP)-2 and SREBP-1c mRNA indicate reduced lipogenesis in the liver of XN-fed ApoE⁻/⁻ mice. Concomitant induction of hepatic mRNA expression of carnitine palmitoyltransferase-1a in ApoE⁻/⁻ mice-administered XN suggests increased fatty acid beta-oxidation. Fecal cholesterol concentrations were also markedly increased in XN-fed ApoE⁻/⁻ mice compared with mice fed western-type diet alone.
CONCLUSION: The atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
ABCG1Humanatherosclerosis treatmentISOAbcg1 (Mus musculus) RGD 
Abcg1Mouseatherosclerosis treatmentIDA  RGD 
Abcg1Ratatherosclerosis treatmentISOAbcg1 (Mus musculus) RGD 
CCL2Humanatherosclerosis treatmentISOCcl2 (Mus musculus) RGD 
CPT1AHumanatherosclerosis treatmentISOCpt1a (Mus musculus) RGD 
Ccl2Mouseatherosclerosis treatmentIDA  RGD 
Ccl2Ratatherosclerosis treatmentISOCcl2 (Mus musculus) RGD 
Cpt1aRatatherosclerosis treatmentISOCpt1a (Mus musculus) RGD 
Cpt1aMouseatherosclerosis treatmentIDA  RGD 
SREBF1Humanatherosclerosis treatmentISOSrebf1 (Mus musculus) RGD 
SREBF2Humanatherosclerosis treatmentISOSrebf2 (Mus musculus) RGD 
ScdRatatherosclerosis treatmentISOScd1 (Mus musculus) RGD 
Scd1Mouseatherosclerosis treatmentIDA  RGD 
Srebf1Ratatherosclerosis treatmentISOSrebf1 (Mus musculus) RGD 
Srebf1Mouseatherosclerosis treatmentIDA  RGD 
Srebf2Mouseatherosclerosis treatmentIDA  RGD 
Srebf2Ratatherosclerosis treatmentISOSrebf2 (Mus musculus) RGD 

Gene-Chemical Interaction Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
ABCG1Humanxanthohumol increases expression ISOAbcg1 (Mus musculus)xanthohumol increases expression of Abcg1 protein in liverRGD 
Abcg1Ratxanthohumol increases expression ISOAbcg1 (Mus musculus)xanthohumol increases expression of Abcg1 protein in liverRGD 
Abcg1Mousexanthohumol increases expression EXP xanthohumol increases expression of Abcg1 protein in liverRGD 
CCL2Humanxanthohumol decreases expression ISOCcl2 (Mus musculus)xanthohumol decreases expression of Ccl2 protein in blood serumRGD 
CPT1AHumanxanthohumol increases expression ISOCpt1a (Mus musculus)xanthohumol increases expression of Cpt1a mRNA in liverRGD 
Ccl2Ratxanthohumol decreases expression ISOCcl2 (Mus musculus)xanthohumol decreases expression of Ccl2 protein in blood serumRGD 
Ccl2Mousexanthohumol decreases expression EXP xanthohumol decreases expression of Ccl2 protein in blood serumRGD 
Cpt1aRatxanthohumol increases expression ISOCpt1a (Mus musculus)xanthohumol increases expression of Cpt1a mRNA in liverRGD 
Cpt1aMousexanthohumol increases expression EXP xanthohumol increases expression of Cpt1a mRNA in liverRGD 
SREBF1Humanxanthohumol decreases expression ISOSrebf1 (Mus musculus)xanthohumol decreases expression of Srebf1 mRNA in liverRGD 
SREBF2Humanxanthohumol decreases expression ISOSrebf2 (Mus musculus)xanthohumol decreases expression of Srebp2 protein in liverRGD 
ScdRatxanthohumol decreases expression ISOScd1 (Mus musculus)xanthohumol decreases expression of Scd1 mRNA in liverRGD 
Scd1Mousexanthohumol decreases expression EXP xanthohumol decreases expression of Scd1 mRNA in liverRGD 
Srebf1Ratxanthohumol decreases expression ISOSrebf1 (Mus musculus)xanthohumol decreases expression of Srebf1 mRNA in liverRGD 
Srebf1Mousexanthohumol decreases expression EXP xanthohumol decreases expression of Srebf1 mRNA in liverRGD 
Srebf2Mousexanthohumol decreases expression EXP xanthohumol decreases expression of Srebp2 protein in liverRGD 
Srebf2Ratxanthohumol decreases expression ISOSrebf2 (Mus musculus)xanthohumol decreases expression of Srebp2 protein in liverRGD 

Objects Annotated

Genes (Rattus norvegicus)
Abcg1  (ATP binding cassette subfamily G member 1)
Ccl2  (C-C motif chemokine ligand 2)
Cpt1a  (carnitine palmitoyltransferase 1A)
Scd  (stearoyl-CoA desaturase)
Srebf1  (sterol regulatory element binding transcription factor 1)
Srebf2  (sterol regulatory element binding transcription factor 2)

Genes (Mus musculus)
Abcg1  (ATP binding cassette subfamily G member 1)
Ccl2  (C-C motif chemokine ligand 2)
Cpt1a  (carnitine palmitoyltransferase 1a, liver)
Scd1  (stearoyl-Coenzyme A desaturase 1)
Srebf1  (sterol regulatory element binding transcription factor 1)
Srebf2  (sterol regulatory element binding factor 2)

Genes (Homo sapiens)
ABCG1  (ATP binding cassette subfamily G member 1)
CCL2  (C-C motif chemokine ligand 2)
CPT1A  (carnitine palmitoyltransferase 1A)
SREBF1  (sterol regulatory element binding transcription factor 1)
SREBF2  (sterol regulatory element binding transcription factor 2)


Additional Information